Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 82.5 kDa. The protein migrates as 90-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally sucrose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus TIE2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Cynomolgus TIE2, His Tag (Cat. No. TI2-C5253) is more than 85% and the molecular weight of this protein is around 93-113 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
Ripretinib | DCC-2618 | Approved | Deciphera Pharmaceuticals | Qinlock, 擎乐 | United States | Gastrointestinal Stromal Tumors | Deciphera Pharmaceuticals Llc | 2020-05-15 | Mastocytosis, Systemic; Neoplasms; Gastrointestinal Stromal Tumors | Details |
Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | Iclusig | United States | Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Ariad Pharmaceuticals Inc | 2012-12-14 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Thyroid Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Medullary thyroid cancer (MTC); Common Bile Duct Neoplasms; Leukemia, Myeloid, Accelerated Phase; Blast Crisis; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Small Cell Lung Carcinoma; Adenocarcinoma of Lung; Hematologic Neoplasms; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic; Solid tumours; Leukemia | Details |
Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
AV-001 (Vasomune Therapeutics) | AV-001 (Vasomune Therapeutics) | Phase 2 Clinical | Sunnybrook Health Sciences Centre | Respiratory Tract Infections; Pneumonia; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Pneumonia, Viral | Details |
Razuprotafib | AKB-9778; EYP-2301 | Phase 2 Clinical | Akebia Therapeutics Inc | Coronavirus Disease 2019 (COVID-19); Glaucoma, Open-Angle; Respiratory Distress Syndrome, Adult; Ocular Hypertension; Diabetic macular oedema; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Solid tumours; Skin Melanoma; Bone metastases; Pancreatic Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Trebananib | AMG-386; 20060439 | Phase 2 Clinical | Amgen Inc, Takeda Pharmaceutical Co Ltd | Fallopian Tube Neoplasms; Carcinoma, Adenosquamous; Sarcoma; Breast Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Genital Neoplasms, Female; Colorectal Neoplasms; Endometrial Neoplasms; Adenocarcinoma, Clear Cell; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Lung Neoplasms; Uterine Neoplasms; Carcinoma, Endometrioid; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Glioblastoma; Ovarian Neoplasms; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Carcinoma, Renal Cell; Renal Insufficiency; Hemangiosarcoma; Rectal Neoplasms; Carcinoma; Leukemia, Myelomonocytic, Acute; Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Colonic Neoplasms; Kidney Diseases; Sarcoma, Endometrial Stromal; Leukemia, Megakaryoblastic, Acute; Oligodendroglioma; Central Nervous System Neoplasms; Neuroendocrine Tumors | Details |
IGT-427 | IGT-427 | Phase 2 Clinical | Ingenia Therapeutics Inc | Retinal Diseases; Wet Macular Degeneration; Diabetic macular oedema | Details |
Gersizangitide | AXT-107 | Phase 2 Clinical | AsclepiX Therapeutics Inc | Diabetic macular oedema; Macular Degeneration | Details |
CEP-11981 | ESK-981; CEP-11981; SSR-106462; BOL-303213X | Phase 2 Clinical | Sanofi | Bone metastases; Neoplasms; Adenoma, Islet Cell; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenosquamous; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms | Details |
PMC-403 | PMC-403 | Phase 1 Clinical | Pharmabcine | Capillary Leak Syndrome; Solid tumours; Wet Macular Degeneration; Macular Degeneration | Details |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
This web search service is supported by Google Inc.